Incretin-based therapies: focus on effects beyond glycemic control alone.
about
Roflumilast: a review of its use in the treatment of COPDA pilot three-month sitagliptin treatment increases serum adiponectin level in Japanese patients with type 2 diabetes mellitus--a randomized controlled trial START-J study.Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain.GLP-1 based therapeutics: simultaneously combating T2DM and obesity.Impact of dipeptidyl peptidase-4 inhibitors on serum adiponectin: a meta-analysis.Peripheral targets in obesity treatment: a comprehensive update.Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes.
P2860
Q26770501-27543B31-8576-4F79-AE22-074B1EF237A0Q33726648-A2B3B81E-77D8-4996-884B-ECF79EB01628Q34745109-75C68F4B-EADB-422A-A8F6-D867F00E8C8EQ35200252-FCF2D00F-71B3-45FB-84E0-4AF22D2F1D7CQ36202964-7515FC8A-1C60-45AD-A7E7-C26D82EB49C5Q38194649-4081A020-FCAA-4464-9F63-4ED314ABCF4DQ42371337-36AFB7B8-9267-47B7-A8DE-DFE3E11876A8
P2860
Incretin-based therapies: focus on effects beyond glycemic control alone.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Incretin-based therapies: focus on effects beyond glycemic control alone.
@en
type
label
Incretin-based therapies: focus on effects beyond glycemic control alone.
@en
prefLabel
Incretin-based therapies: focus on effects beyond glycemic control alone.
@en
P2860
P1433
P1476
Incretin-based therapies: focus on effects beyond glycemic control alone.
@en
P2093
Jaime A Davidson
P2860
P2888
P304
P356
10.1007/S13300-013-0040-0
P577
2013-09-21T00:00:00Z
P5875
P6179
1028184579